RecruitingNot ApplicableNCT02914483

Women's Heart Attack Research Program: Stress Ancillary Study

Women's Heart Attack Research Program: Stress Ancillary Study; Telephone-Based Stress Management for Women With Myocardial Infarction


Sponsor

NYU Langone Health

Enrollment

200 participants

Start Date

Aug 1, 2016

Study Type

INTERVENTIONAL

Conditions

Summary

The Women's HARP study is a multi-center study focusing on women with clinical presentation of myocardial infarction (MI). Women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ECGs). 2 months following MI, participants will be screened for the Stress Ancillary Study and enrolled if an elevated level of perceived stress is reported. After completing baseline assessments, participants will be randomized to Enhanced Usual Care (EUC) or stress management for 8 weeks. Participants will be followed for 6 months.


Eligibility

Sex: FEMALEMin Age: 21 YearsMax Age: 99 Years

Inclusion Criteria8

  • Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms
  • Objective evidence of MI (either or both of the following):
  • Elevation of troponin to above the laboratory upper limit of normal
  • ST segment elevation of ≥1mm on 2 contiguous ECG leads
  • Willing to provide informed consent and comply with all aspects of the protocol
  • Age ≥ 21 years
  • Female sex
  • PSS-4 score ≥6 at 2 month follow up visit after MI

Exclusion Criteria6

  • Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma.
  • Moderately severe or severe depressive symptoms (PHQ-9 ≥ 15)
  • Active suicidal ideation (PHQ-9 item #9 or otherwise reported during screening)
  • History of or current diagnosis of psychosis (EHR review)
  • Significant cognitive impairment (EHR review or evident during screening)
  • Current participation in another behavioral clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALEnhanced Usual Care

Participants randomized into the EUC group will complete 8 weekly individual sessions by phone. Each weekly session consists of: brief check-in and review of AHA brochure- "Women, Heart Disease and Stroke".

BEHAVIORALStress Management

Participants randomized into the stress management group will complete 8 weekly group sessions by phone. The intervention is a telephone adaptation of mindfulness-based cognitive therapy (MBCT) and focuses on building cognitive-behavioral and mindfulness skills to help manage and cope with stress. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and home-based practice assignment.

DIAGNOSTIC_TESTActigraph

The Actigraph (wGT3X-BT) will monitor sleep activity and will be worn by participants for 7 days, pre- and post stress based intervention.


Locations(14)

Cedars-Sinai Medical Center

Los Angeles, California, United States

Univeristy of Florida

Gainesville, Florida, United States

Emory University

Atlanta, Georgia, United States

Johns Hopkins Medical Center

Baltimore, Maryland, United States

Dartmouth-Hitchcock

Lebanon, New Hampshire, United States

NYU Winthrop

Mineola, New York, United States

NYU Langone Medical Center

New York, New York, United States

Columbia University Medical Center

New York, New York, United States

Ohio State University Medical Center

Columbus, Ohio, United States

St. Luke's University Health Network

Bethlehem, Pennsylvania, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Seton Heart (Ascension) - University of Texas, Austin

Austin, Texas, United States

University of Alberta

Edmonton, Alberta, Canada

University of Calgary

Calgary, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02914483


Related Trials